Vaccines for control of fertility are likely to have an important impact
on family planning methods. They are designed to act by mobilization of
an internal physiological process and do not require external
medication on a continuous basis. A number of birth control vaccines are
at different stages of development, the most advanced being a vaccine
inducing antibodies against human chorionic gonadotrophin (hCG). This
vaccine consists of a heterospecies dimer (HSD, beta hCG associated with
alpha-subunit of ovine luteinizing hormone, beta hCG:alpha oLH) linked
to tetanus toxoid (TT) or diphtheria toxoid (DT) as carriers. The
vaccine has recently passed an important milestone; it has completed the
first leg of phase II efficacy trials. Women of proven fertility
leading active sexual life were protected from becoming pregnant at
antibody titres > or = 50 ng of hCG bioneutralization capacity per
ml. This vaccine has previously been demonstrated to be reversible in
its effect. It is free from any notable side-effects on endocrine,
cardiovascular and other body functions. Ovulation was not disturbed and
menstrual regularity was maintained. A logistic disadvantage of the
present vaccine is the requirement for multiple injections. This is
expected to be overcome by encapsulation of the requisite doses of the
vaccine in biodegradable microspheres, which could be given at a single
contact point for sustained antibody titres lasting over a year. A live
recombinant vaccine has also been made that elicits high anti-hCG titres
in monkeys for nearly 2 years following primary immunization and a
booster at 8-9 months.
No comments:
Post a Comment